Jiangsu Yahong Meditech Co., Ltd. (SHA:688176)

Market Cap	6.74B +6.7%
Revenue (ttm)	287.11M +20.5%
Net Income	-445.25M
EPS	-0.79
Shares Out	562.50M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	13,261,857
Open	11.99
Previous Close	11.96
Day's Range	11.72 - 12.21
52-Week Range	8.93 - 18.11
Beta	0.33
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 29, 2026

About Jiangsu Yahong Meditech

Jiangsu Yahong Meditech Co., Ltd., a pharmaceutical company, focuses on urogenital tumors and women's health in China and internationally. It develops APL-1702, a photodynamic drug-device combination product for the treatment of high-grade squamous intraepithelial lesions of the cervix and for HPV viral clearance; APL-2302, an oral small-molecule inhibitor of the deubiquitinating enzyme ubiquitin-specific protease 1 (USP1) for the treatment of ovarian and breast cancer; APL-2501 for the treatment of ovarian cancer; AT-018 for the treatment of b...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2010
• Employees: 497
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688176

Financial Performance

In 2025, Jiangsu Yahong Meditech's revenue was 277.12 million, an increase of 37.49% compared to the previous year's 201.56 million. Losses were -416.38 million, 8.41% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 29, 2026

Data Sources Report a data error